Europe/London (GMT) time zone

Day 1: 24 June 2022

10:00-11:00 - Hall A

Opening Session

Chairs: Stefan Anker, Germany, & Fausto Pinto, Portugal

10:00-10:20 – “Prometheus” basic science key note lecture:
Targeting the ubiquitin proteasome system to fight muscle atrophy: update 2022
Volker Adams, Germany

10:25-10:45 – “Hippocrates” clinical science key note lecture:
From sarcopenia to frailty
John Morley, USA

10:50-10:58 – JCSM & SCWD lecture
Stephan von Haehling, Germany

11:00-11:15

Coffee Break

11:15-12:00​ - Hall A

A -
Sarcopenia of aging and chronic diseases

Chairs: Paola Costelli, Italy, & Kamyar Kalantar-Zadeh, USA

11:15-11:24 – MOTS-c: a new player in aging-related loss of muscle mass and function 
Changhan David Lee, USA 

11:26-11:35 – Metabolic and molecular consequences of sarcopenia in alcoholic liver disease
Srinivasan Dasarathy, USA

11:37-11:46 – Bone and muscle crosstalk: Biological and clinical implications
Gustavo Duque, Australia

11:48-11:57 – Results of the SPRINTT trial
Francesco Landi, Italy

11:15-12:00 - Hall B

B - Clinical Session
Novel aspects of adipose tissue function in wasting

Chairs: Stephan Herzig, Germany, & Robert Mak, USA

11:15-11:24 – Immune-sympathetic neuron communication guides adipose tissue browning in cancer-associated cachexia
Martina Schweiger, Austria

11:26-11:35 – Angiocrine signals promote adipose tissue wasting in cancer cachexia
Andreas Fischer, Germany

11:37-11:46 – Brown adipose tissue activation is not related to hypermetabolism in emphysematous COPD patients
Annemie Schols, The Netherlands 

11:48-11:57 – MRI-determined psoas muscle fat infiltration correlates with severity of weight loss during cancer cachexia
Dimitrios Karampinos, Germany

12:00-13:00

Lunch Break

13:00-13:45 - Hall A

C - 
Recent guidelines and consensus developments

Chairs: Kamyar Kalantar-Zadeh, USA, & Stephan von Haehling, Germany

13:00-13:12 – Appetite is key in geriatric syndromes: a pre-release of SCWD International guidelines on anorexia of aging
Ivan Aprahamian, Brazil

13:15-13:27 – Development of the cachexia consensus in Asia
Hidenori Arai, Japan

13:30-13:42 – Recent guidelines on cancer cachexia: ESPEN, ESMO and ASCO
Alessandro Laviano, Italy

13:00-13:45 - Hall B

D - Clinical Session
Mechanisms of muscle loss due to cancer and chemotherapy and early interventions to help counteract negative effects

Chairs: Fabio Penna, Italy, & Vera Mazurak, Canada

13:00-13:09 – Doxorubicin-induced skeletal muscle atrophy, underlying molecular pathways and potential protective effects of exercise: Evidence from pre-clinical and clinical data
Anouk Hiensch, The Netherlands

13:11-13:20 – Exercise and Nutrition-based Rehabilitation programme (EneRgy) in people with cancer 
Barry Laird, UK

13:22-13:31 – Resistance training during chemotherapy for non-metastatic colon cancer: The FORCE study: Effects on body composition and physical function
Bette Caan, USA

13:33-13:42 – Effects of exercise in patients after curative treatment for esophageal cancer: body composition and adequacy of energy and protein intake (the PERFECT study)
Anne May, The Netherlands

13:45-14:45

Coffee Break

13:50-14:40 - Poster Area

Poster Session 1

Poster session 1.1
Cancer cachexia I (posters 4-14 to 4-23 + 5-04)
Chairs: Andrea Bonetto, Andreas Fischer

Poster session 1.2
Diagnosis of cachexia and sarcopenia I (posters 1-25 to 1-34)
Chairs: Wolfram Doehner, Peter Martin

Poster session 1.3
Cachexia – mechanisms I (posters 3-09 to 3-18)
Chairs: Alessio Molfino, Marco Sandri

Poster session 1.4
Therapeutic development I (posters 6-01 to 6-10)
Chairs: Andrew Judge, Jochen Springer

13:50-14:40 - Hall A

Rapid Fire Abstracts Session 1

Chairs: Denis Guttridge, USA, & Julia von Maltzahn, Germany

13:50-13:55 – Body composition assessment by artificial intelligence from routine CT scans in colorectal cancer, introducing BodySegAI (1-04)
Dena Helene Alavi, Norway

13:55-14:00 – Towards artificial intelligence: point-of-care musculoskeletal ultrasound correlates with body composition, muscle strength and physical performance in children with acute lymphoblastic leukemia (1-12) 
Emma J. Verwaaijen, The Netherlands

14:00-14:05 – Two years of aging – initial results on changes in muscle composition in the UK Biobank imaging study (1-26)
Dahlqvist Leinhard, Sweden

14:05-14:10 – Long-haul COVID-19 is related to lower pectoralis muscle mass at hospital admission for treatment of acute infection (2-07)
Marilia Seelaender, Brazil

14:10-14:15 – Chronic activation of ALK5/TGFbRI signaling in adult mouse skeletal muscle induces severe muscle wasting with concomitant impaired mitochondrial integrity (2-12)
Laetitia Mazelin, France

14:15-14:20 – The effect of severe burns on skeletal muscle protein balance in female rats 10 and 40 days post-burn (2-14)
Dorien Dombrecht, Belgium

14:20-14:25 – Sex differences in skeletal muscle-ageing trajectory: same processes, but with different magnitudes (2-19)
Jelle de Jong, The Netherlands

14:25-14:30 – Mechanosignaling through YAP/TAZ drives fibroadipogenic progenitors activation and promotes paraspinal muscle fibrosis in degenerative scoliosis (2-21)
Abdukahar Kiram, China

14:45-15:30 - Hall A

E - Basic Science Session
New basic findings in muscle wasting

Chairs: Andrew Judge, USA, & Gustavo Nader, USA

Activation of Akt-mTORC1 signaling reverts cancer-dependent muscle wasting
Bert Blaauw, Italy

New insights into the role of GCN2-eIF2alpha signaling in the regulation of autophagy
Anne-Catherine Maurin, France

Interventions for improving mitochondrial function to counteract cancer and chemotherapy-induced cachexia
Fabio Penna, Italy

Fighting muscle loss: lessons from hibernation in brown bear
Etienne Lefai, France

14:45-15:30 - Hall B

F - Clinical Session
A focus on muscle health: assessment approaches and targeted nutrition interventions

Chairs: Maurizio Muscaritoli, Italy, & Anne May, The Netherlands

Measuring muscle in oncology research and interventions
Elizabeth Cespedes Feliciano, USA

Artificial Intelligence approaches to improve speed, dimensionality and entry into clinical workflows
Faisal Beg, Canada

Surrogate markers of muscle mass and quality
M. Cristina Gonzalez, Brazil

A mechanistic perspective of specialized nutrition for muscle health
Philip Atherton, UK

15:30-16:30

Coffee Break

15:35-16:25 - Poster Area

Poster Session 2

Poster session 2.1
Muscle wasting & sarcopenia – mechanisms I (posters 2-20 to 2-29)
Chairs: Achim Krüger, Changhan David Lee

Poster session 2.2
Cancer cachexia II (posters 4-24 to 4-36)
Chairs: Andrea Bonetto, Andreas Fischer

Poster session 2.3
Physical activity & training (posters 7-01 to 7-09)
Chairs: Anne May, Ashley Smuder

Poster session 2.4
Diagnosis of cachexia and sarcopenia II (posters 1-01 to 1-12 + 1-26)
Chairs: Wolfram Doehner, Peter Martin

15:35-16:25 - Hall A

Rapid Fire Abstracts Session 2

Chairs: Laure Bindels, Belgium, & Gustavo Duque, Australia

15:35-15:40 – The relationship between cachexia and inflammatory biomarkers in patients with cancer; initial findings from the REVOLUTION cachexia characterisation study (4-04)
Robert Paval, UK

15:40-15:45 – Identifying cancer patients with cachexia at scale by leveraging self-supervised natural language processing and predictive models on unstructured data in patients’ electronic health records (4-08)
Richard Skipworth; Barry Laird, UK

15:45-15:50 – Examining the negative impact of weight loss and cachexia in Chimeric Antigen Receptor (CAR) T-cell therapy (4-09)
Brittany Cucchiaro, UK

15:50-15:55 – Evaluation of weight gain and overall survival of patients with advanced non-small-cell lung cancer (NSCLC) treated with first-line platinum-based chemotherapy (4-11)
Eric Roeland, USA

15:55-16:00 – Assessment of muscle and lean mass in colon cancer patients on chemotherapy: correlations of d3-creatine, dual energy x-ray absorptiometry and computed tomography (4-16)
Elisabeth M. Cespedes Feliciano, USA

16:00-16:05 – NAD+ repletion with niacin counteracts cancer cachexia (4-19)
Marc Beltrà Bach, Italy

16:05-16:10 – Respiratory Muscle Pathology in Esophageal Adenocarcinoma Patients (4-31)
Miles Cameron, USA

16:10-16:15 – Ketogenic diet slows down tumor growth but induces primary adrenal insufficiency that accelerates onset of cachexia in C26 and KPC murine models (3-05)
Miriam Ferrer Gonzalez, USA

16:15-16:20 – Colon cancer treatment with FOLFIRI exacerbates muscle fiber atrophy and induces a catabolic transcriptional program in skeletal muscle (3-08)
Vickie Baracos, Canada

16:30-17:15 - Hall A

G - Basic Science Session
Ammonia and the muscle - multiple diseases, one mechanism

Chairs: Andreas Fischer, Germany, & Yi-Ping Li, USA

Mechanisms of ammonia induced sarcopenia – a common mediator in multiple diseases 
Srinivasan Dasarathy, USA

Amino acid perturbations in hyperammonemia 
Milan Holecek, Czech Republic

Multiomics based approaches to identify novel cellular and tissue responses 
Nicole Welch, USA

The significance of myosteatosis in surgical cancer patients
Steven Olde Damink, The Netherlands

16:30-17:15 - Hall B

H - Clinical Session
Special diets - the power of food

Chair: Paula Ravasco, Portugal

What determines/Which parameters determine optimal protein metabolism in the old?
Dominique Dardevet, France

Manipulating the microbiome to counteract frailty
Patrizia Brigidi, Italy

Nutrition and anorexia of ageing 
Reshma Merchant, Singapore

Combining power food and fasting in cachexia: no go or wise go?
Florian Strasser, Switzerland

Day 2: 25 June 2022

9:00-9:45 - Hall A

J - Clinical Session
Liver alterations as drivers of cancer cachexia

Chairs: Andrea Bonetto, USA, & M. Cristina Gonzalez, Brazil

Hepatic and intestinal microbial disturbances as therapeutic targets in cancer cachexia 
Laure Bindels, Belgium

A cachexia score based on liver alterations predicts prognosis of gastrointestinal cancer patients
Achim Krüger, Germany

Inflammation and impairment of hepatic metabolism and function in cachectic cancer patients
Marilia Seelaender, Brazil

Transcriptional reprogramming of hepatocyte function in cancer cachexia
Sören Fisker Schmidt, Denmark

9:45-10:00

Coffee Break

10:00-10:45 - Hall A

K - Basic Science Session
Hot topics in basic research: role of muscle stem and progenitor cells during aging, disease and regeneration

Chairs: Joe Chakkalakal, USA, & Nicholas Greene, USA

Muscle stem cells in age and disease 
Julia von Maltzahn, Germany 

Neurofibromatosis type 1 associated myopathy is due to metabolic reprogramming of muscle stem cells in a mouse model
Sigmar Stricker, Germany 

Fibro-adipogenic progenitors coordinate muscle regeneration 
Georgios Kotsaris, Germany 

Muscle stem cells drive post-sepsis skeletal muscle recovery and regeneration
Jason Doles, USA

10:00-10:45 - Hall B

L - Clinical Session
Inter-organ crosstalks in cancer cachexia


Chairs: Frank Misselwitz, Germany, & Gustavo Nader, USA

Abnormal liver-bone-muscle axis in cancer cachexia 
Andrea Bonetto, USA

Impact of exercise and chemotherapy on the respiratory neuromuscular system
Ashley Smuder, USA            

Cancer-induced muscle and bone deficits
Hanna Taipaleenmäki, Germany

A prospective study of hand-grip strength to predict mortality in patients with cancer with and without cachexia
Markus Anker, Germany

10:45-11:45

Coffee Break

10:50-11:40 - Poster Area

Poster Session 3

Poster session 3.1
Muscle wasting and sarcopenia – mechanisms II (posters 2-01 to 2-09)
Chairs: Denis Guttridge, Milan Holecek

Poster session 3.2
Nutrition & appetite (posters 5-01 to 5-09)
Chairs: Philip Atherton, Adrian Slee

Poster session 3.3
Diagnosis of cachexia and sarcopenia III (posters 1-14 to 1-24)
Chairs: Dimitrios Karampinos, Martina Schweiger

10:50-11:40 - Hall A

Rapid Fire Abstracts Session 3

Chairs: Anouk Hiensch, The Netherlands, & Richard Skipworth, UK

10:50-10:55 – Muscle Wasting in Early-stage Cancer is Associated with Disorganized Extracellular Matrix Distinct from Fibrosis (4-25)
Erin E Talbert, USA

10:55-11:00 – Study of the histological and inflammatory rearrangements of the subcutaneous adipose tissue among gastrointestinal cancer patients with cachexia (4-32)
Alessio Molfino, Italy

11:00-11:05 – Targeted dietary intervention attenuates experimental lung cancer cachexia (5-04)
Wouter van de Worp, The Netherlands

11:05-11:10 – Leptin, Adiponectin, and Mortality Risk in a Prospective Hemodialysis Cohort (5-07)
Connie Rhee, USA

11:10-11:15 – Deletion of FNDC5/Irisin protects against cancer induced cachexia syndrome (6-09)
Fabrizio Pin, USA

11:15-11:20 – Effects of Bioarginine C supplementation on functional parameters in adults with Long Covid: a randomised clinical trial (6-15)
Matteo Tosato, Italy

11:20-11:25 – Metoprolol attenuates stimulated lipolysis in adipose tissue from cachectic patients with pancreatic cancer (6-08)
Lenka Rossmeislova, Czech Republic

11:45-12:30 - Hall A

M - Basic Science Session
Cachexia as an heterogeneous disease: underlying mechanisms

Chairs: Jochen Springer, Germany, & Marilia Seelaender, Brazil

Sex-dependent response of adipose tissue and lipid metabolism in cancer cachexia
Vera Mazurak, Canada

Tumor microenvironment evolution and its relevance to cachexia 
Mariam Jamal-Hanjani, UK

Sex variation in cachexia
Silvia Busquets, Spain

Tumor-specific ribosomal deficits in muscle wasting 
Gustavo Nader, USA

11:45-12:30 - Hall B

N - Clinical Session
State of the art nutrition for outcome driven cancer treatments

Chairs: Gustavo Duque, Australia, & Barry Laird, UK

Integrated evaluation of body composition in the oncology setting: paradigm change 
David da Silva Dias, Portugal

Nutrition options in 2022: What is on the market?
Paula Ravasco, Portugal

Nutrition in ambulatory cytotoxic treatment: New data on the role of the clinical pharmacist
Leila Costa, Portugal

Head and neck cancer and cachexia – a high risk cancer and higher risk treatments 
Maartje van Beers, The Netherlands

12:40-13:40 - Hall A

Lunchtime Satellite Symposium

Cachexia – Unmet Needs and Opportunities for Novel Therapy

Circulating GDF15 and its relationship with cachexia in non-small cell lung cancer
Mariam Jamal-Hanjani, UK

GDF-15 is a key regulator of cancer cachexia and beyond
Bei Zhang, USA

Questions & Answers

Supported by an educational grant from Pfizer

13:50-14:35 - Hall A

O - Basic Science Session
Novel cachexia mediators - proteins and beyond

Chairs: Denis Guttridge, USA, & Maria Rohm, Germany

Reprogramming of liver and neutrophil metabolism in cancer cachexia
Tobias Janowitz, USA

Tumor-derived cachexia mediators and biomarkers
Mauricio Berriel Diaz, Germany

Tumor-derived extracellular vesicles 
Paola Costelli, Italy 

KLF10: a novel mediator of cancer-associated skeletal muscle wasting 
Jason Doles, USA

13:50-14:35 - Hall B

P - Clinical Session
Cancer progression and cachexia

 

Chairs: Vickie Baracos, Canada, & Ashley Smuder, USA

Exercise and tumor control: expanding the field of exercise oncology to cancer progression and cachexia
Lee Jones, USA

Cardiac wasting in cancer
Alessia Lena, Germany

A review of the evidence for multi-modal interventions in cachexia management
Joanne Reid, UK

ACTAs for cancer cachexia
Andrew Coats, Australia

14:35-15:35

Coffee Break

14:40-15:30 - Poster Area

Poster Session 4

Poster session 4.1
Therapeutic development II (posters 6-11 to 6-19)
Chairs: Yi-Ping Li, Anne-Catherine Maurin

Poster session 4.2
Cachexia – mechanisms II (posters 3-02 to 3-08)
Chairs: Silvia Busquets, Marco Sandri

Poster session 4.3
Cancer cachexia III (posters 4-01 to 4-12 + 4-31)
Chairs: Sören Fisker Schmidt, Fabio Penna

Poster session 4.4
Muscle wasting & sarcopenia – mechanisms III (posters 2-11 to 2-19)
Chairs: Rodney Infante, Sigmar Stricker

15:35-16:20 - Hall A

Q - Basic Science Session
Mechanisms of energy and anabolic crisis in cancer cachexia – new therapeutic targets?

Chairs: Paola Costelli, Italy, & Tobias Janowitz, USA

MyomiRNA, systemic and local inflammation and muscle wasting 
Maurizio Muscaritoli, Italy

The transcriptional repressor FoxP1 in cancer-induced skeletal muscle wasting and weakness
Sarah Judge, USA

Beyond good and evil: Discovering novel anabolic targets to overcome cancer related-muscle wasting
Marcelo Pereira, UK

Skeletal muscle mitochondrial dysfunction and lipid accumulation in breast cancer 
Emidio Pistilli, USA

15:35-16:30 - Hall B

R - Clinical Session
Designing trials for cancer cachexia

Chairs: Teresa Zimmers, USA, Bette Caan, USA, & Andrew Coats, Australia

Muscle mass criterion for cachexia: measuring muscle mass in clinical trials 
Vickie Baracos, Canada

Selecting populations for clinical trials 
Eric Roeland, USA

Endpoints for cancer cachexia clinical trials 
Stefan Anker, Germany

Use of biomarkers to assess treatment effect in cancer cachexia 
Jose Garcia, USA

Regulatory perspective on Cancer Cachexia Trials 
Giuseppe Rosano, UK

16:20-16:35

Coffee Break

16:35-17:20 - Hall A

S - Basic Science Session
Cachexia & muscle wasting – pathophysiology update

Chairs: Marco Sandri, Italy, & Denis Guttridge, USA

T cells and cachexia
Laura Antonio-Herrera, Austria

Aging exacerbates neuromuscular junction disruption after injury that stimulates inflammation
Joe Chakkalakal, USA

Macrophages and muscle regeneration
Emanuele Berardi, Belgium

Endothelial dysfunction in cachexia
Young-Mee Kim, USA

16:35-17:20 - Hall B

T - Young Investigators Award Session

Judges: Hidenori Arai, Japan, Vickie Baracos, Canada, Bette Caan, USA, Jose Garcia, USA, Paula Ravasco, Portugal, & Jochen Springer, Germany

16:35-16:42 – MicroRNA-22 as a potential diagnostic tool in males with sarcopenic heart failure: Results from the Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF) (1-29)
Mirela Vatic, Germany

16:44-16:51 – STumor metabolic activity is associated with myosteatosis and reduced survival in patients with non-small cell lung cancer (4-15)
Yan Sun, The Netherlands

16:53-17:00 – OPA1 overexpression may protect against cancer-induced muscle wasting (4-22)
Stavroula Tsitkanou, USA

17:02-17:09 – Intramuscular lipid alterations in human pancreatic cancer cachexia (4-34)
Min Deng, The Netherlands

17:11-17:18 – Leucine-rich diet improves cachexia index and alters tumour thermogenic capacity in Lewis Lung tumour-bearing aged mice (5-03)
Natalia Angelo da Silva Miyaguti, Brazil

17:20-17:35

Coffee Break

17:35-18:20 - Hall A

U - Basic Science Session
Host-specific and tumor-specific molecular mechanisms of biological variability in cancer cachexia

Chair: Puneeth Iyengar, USA

Host factors: sexual dimorphism in murine models of cancer cachexia
Nicholas Greene, USA

Host factors: aging and host genotype in cancer cachexia
Maria Rohm, Germany

Tumor factors: tumor molecular and cellular heterogeneity mediates cancer cachexia phenotype
Teresa Zimmers, USA

Identification of molecules that contribute to NSCLC cancer cachexia
Rodney Infante, USA

17:35-18:20 - Hall B

V - Clinical Session
Cachexia in chronic kidney disease: recent advances

Chairs: Philip Atherton, UK, & Stephan von Haehling, Germany

Impact of protein intake on CKD cachexia and sarcopenia 
Kam Kalantar-Zadeh, USA                  

Physical activity and nutrition in CKD  
Angela Wang, Hong Kong

Inflammation and adipose tissue browning in CKD cachexia  
Robert Mak, USA 

Activin signaling and GDF-15 in CKD cachexia 
Connie Rhee, USA

Day 3: 26 June 2022

9:00-9:50 - Hall A

W
Covid-19 and cachexia: common players and perspectives

Chair: Hidenori Arai, Japan & Annemie Schols, The Netherlands

The role of adipose tissue in Covid-19 cytokine storm: learning from cachexia 
Marilia Seelaender, Brazil

Nutrition: a matter of life or death  
Alessandro Laviano, Italy

Body composition and muscle quality in Covid-19 patients 
Martine Sealy, The Netherlands

Frailty and rehabilitation in Covid-19 patients 
Francesco Landi, Italy

9:50-10:00

Break

10:00-10:50 - Hall A

X
Multi-modal interventions for cachexia

Chairs: Joanne Reid, UK, & Martine Sealy, The Netherlands

Evolution and outcomes from a multi-disciplinary cachexia clinic
Peter Martin, Australia 

Clarifying the role of palliative rehabilitation in cachexia management
Cathy Payne, Belgium

The importance of exercise and nutrition in an integrated response to cachexia management 
Adrian Slee, UK

Patient experience of a multi-professional cachexia clinic
Vanessa Vaughan, Australia

10:50-11:00

Break

11:00-11:50 - Hall A

Y
Mechanisms of cancer cachexia – transition from basic research to clinical investigation

Chair: Teresa Zimmers, USA, & Steven Olde Damink, The Netherlands

MEF2c-dependent downregulation of myocilin mediates cancer-induced muscle wasting and associates with cachexia in patients with cancer
Andrew R. Judge, USA 

Activation of p38β MAPK in skeletal muscle correlates with weight loss in cancer patients 
Yi-Ping Li, USA

Association between growth differentiation factor-15 (GDF-15) serum levels, anorexia and low muscle mass among cancer patients
Alessio Molfino, Italy

Adipose depot gene expression and intelectin-1 in the metabolic response to cancer and cachexia
Richard J. E. Skipworth, UK

12:00-12:45 - Hall A

Lunchtime Session

BIO101 in development for the treatment of sarcopenia

Chair: Francesco Landi, Italy

Speakers: Waly Dioh, France, & Cendrine Tourette, France

Supported by an educational grant from Biophytis

13:00-13:50 - Hall A

Late Breaking Trials Session

Chairs: Stefan Anker, Germany, Andrew Coats,  & Jose Garcia, USA

From ROMANA to SCALA program: The journey of Anamorelin – the ghrelin receptor agonist – towards treating the malignancy associated weight loss and anorexia in adult patients with non-small cell lung cancer (NSCLC)
Daniela Domnica Rotaru, Italy

Use of chirally pure S-enantiomers in the treatment of cancer cachexia: Clinical Development of S-pindolol benzoate in cancer cachexia in patients with advanced Non-Small Cell Lung and Colo-Rectal Cancer
Frank Misselwitz, Germany

Efficacy of empagliflozin in heart failure with preserved ejection fraction according to frailty status – insights from EMPEROR-Preserved trial
Andrew Coats, Australia

13:50-14:00

Break

14:00-14:50 - Hall A


Targeting cachexia treatment: GDF15 and beyond

Chairs: Maurizio Muscaritoli, Italy, & Jochen Springer, Germany

GDF15 neutralization as a transformative therapeutic approach
Bei Zhang, Pfizer, USA

Activation of the hypothalamic–pituitary–adrenal axis by exogenous and endogenous GDF15  
Danna Breen, USA

MC4R antagonism for appetite and body weight regulation – from human genetics to aged rat model
Zhidan Wu, USA

Beyond cachexia: the inhibition of antitumoral immune responses by cachexia-inducing tumor-derived factor GDF-15
Christine Schuberth-Wagner, Germany

15:00-15:50 - Hall A

Highlights Session

Chairs: Vickie Baracos, Canada & Andrew Coats, Australia

Basic Science
Maria Rohm, Germany

Clinical & Biomarkers  
Stephan von Haehling, Germany

Sarcopenia
Maurizio Muscaritoli, Italy

Treatment  
Frank Misselwitz, Germany

Poster Award

Young Investigator Award
Farewell

Consent Management Platform by Real Cookie Banner